Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen

Trial Profile

Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Ibuprofen; Vitamin D
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms DIABGAD; DIABGAD-1
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 May 2018 According to a Diamyd Medical media release, results from this study were published in the Journal of Diabetes Research.
    • 07 May 2018 Results presented in a Diamyd Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top